Gilead Sciences (GILD) : Pensionfund Sabic reduced its stake in Gilead Sciences by 4.77% during the most recent quarter end. The investment management company now holds a total of 35,900 shares of Gilead Sciences which is valued at $3.4 Million after selling 1,800 shares in Gilead Sciences according to a report filed by the company on Apr 4, 2016 with the SEC.Gilead Sciences makes up approximately 1.05% of Pensionfund Sabic’s portfolio.
Other Hedge Funds, Including , Pensionfund Dsm Netherlands reduced its stake in GILD by selling 3,000 shares or 3.79% in the most recent quarter. The Hedge Fund company now holds 76,100 shares of GILD which is valued at $7.3 Million. Gilead Sciences makes up approx 0.99% of Pensionfund Dsm Netherlands’s portfolio.Renaissance Investment Group reduced its stake in GILD by selling 65 shares or 0.2% in the most recent quarter. The Hedge Fund company now holds 31,807 shares of GILD which is valued at $3 Million. Gilead Sciences makes up approx 1.50% of Renaissance Investment Group’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .
Gilead Sciences closed down -0.26 points or -0.27% at $95.83 with 87,96,261 shares getting traded on Monday. Post opening the session at $96.41, the shares hit an intraday low of $95.74 and an intraday high of $97.05 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.